TNFRSF8 and Hodgkins lymphoma: In a multicenter study, our group characterized the outcome of patients receiving CD30 CAR-T therapy and found an overall response rate of 72% for patients with relapsed/refractory Hodgkin lymphoma at 6 weeks posttreatment, with 36% progression-free survival over 1 year [17].